tiprankstipranks
Advertisement
Advertisement

IMVT Stock Latest News

Bernstein initiates Immunovant with a Market Perform, $28 price target
The FlyBernstein initiates Immunovant with a Market Perform, $28 price target
8d ago
IMVT
Immunovant initiated with a Market Perform at Bernstein
PremiumThe Fly
Immunovant initiated with a Market Perform at Bernstein
9d ago
IMVT
Undervalued Potential in Difficult-to-Treat RA: Buy Rating on Immunovant Driven by IMVT-1402’s Differentiated Profile and Underappreciated Market Opportunity
PremiumRatings
Undervalued Potential in Difficult-to-Treat RA: Buy Rating on Immunovant Driven by IMVT-1402’s Differentiated Profile and Underappreciated Market Opportunity
2M ago
IMVT
Immunovant Rides Brepocitinib Momentum Into 2026
PremiumCompany Announcements
Immunovant Rides Brepocitinib Momentum Into 2026
2M ago
IMVT
Immunovant price target raised to $23 from $22 at Truist
PremiumThe Fly
Immunovant price target raised to $23 from $22 at Truist
2M ago
IMVT
Immunovant price target raised to $44 from $41 at Guggenheim
PremiumThe FlyImmunovant price target raised to $44 from $41 at Guggenheim
2M ago
IMVT
Advancing a Differentiated FcRn Pipeline: Late-Stage Catalysts and Solid Fundamentals Support Buy Rating on Immunovant
Premium
Ratings
Advancing a Differentiated FcRn Pipeline: Late-Stage Catalysts and Solid Fundamentals Support Buy Rating on Immunovant
2M ago
IMVT
Immunovant reports Q3 EPS (61c), consensus (70c)
Premium
The Fly
Immunovant reports Q3 EPS (61c), consensus (70c)
2M ago
IMVT
Is IMVT a Buy, Before Earnings?
PremiumPre-Earnings
Is IMVT a Buy, Before Earnings?
2M ago
IMVT
Apellis, Olema, Exicure, Immunovant, LivePerson Insider Shake-Up
PremiumWeekend Updates
Apellis, Olema, Exicure, Immunovant, LivePerson Insider Shake-Up
2M ago
APLS
IMVT
Immunovant price target raised to $22 from $16 at Truist
PremiumThe Fly
Immunovant price target raised to $22 from $16 at Truist
3M ago
IMVT
Immunovant upgraded to Outperform at Wolfe on improving Graves’ perception
PremiumThe Fly
Immunovant upgraded to Outperform at Wolfe on improving Graves’ perception
3M ago
ARGX
IMVT
Immunovant upgraded to Outperform from Peer Perform at Wolfe Research
PremiumThe FlyImmunovant upgraded to Outperform from Peer Perform at Wolfe Research
3M ago
IMVT
Immunovant price target lowered to $41 from $44 at Guggenheim
Premium
The Fly
Immunovant price target lowered to $41 from $44 at Guggenheim
3M ago
IMVT
Immunovant Raises $550 Million Through Stock Offering
Premium
Company Announcements
Immunovant Raises $550 Million Through Stock Offering
4M ago
8K
IMVT
Immunovant’s Strategic Advancements and Promising Pipeline Drive Buy Rating
PremiumRatings
Immunovant’s Strategic Advancements and Promising Pipeline Drive Buy Rating
4M ago
IMVT
Immunovant Announces $550 Million Stock Offering
PremiumCompany Announcements
Immunovant Announces $550 Million Stock Offering
4M ago
8K
IMVT
Immunovant Restructures R&D Leadership with CMO Departure
PremiumCompany Announcements
Immunovant Restructures R&D Leadership with CMO Departure
4M ago
8K
IMVT
Immunovant’s Earnings Call Highlights Clinical Success and Financial Strength
PremiumCompany Announcements
Immunovant’s Earnings Call Highlights Clinical Success and Financial Strength
5M ago
IMVT
Immunovant’s Promising Clinical Progress and Market Potential Justifies Buy Rating
PremiumRatingsImmunovant’s Promising Clinical Progress and Market Potential Justifies Buy Rating
5M ago
IMVT
Immunovant Reports Q2 2025 Financials and Clinical Progress
Premium
Company Announcements
Immunovant Reports Q2 2025 Financials and Clinical Progress
5M ago
IMVT
Immunovant reports Q2 EPS (73c), consensus (73c)
Premium
The Fly
Immunovant reports Q2 EPS (73c), consensus (73c)
5M ago
IMVT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >